Scott Dylla
Directeur/Bestuurslid bij KINETA, INC.
Vermogen: 2 560 $ op 30-04-2024
Profiel
Scott J.
Dylla was the founder of Stemcentrx, Inc. (founded in 2008) where he held the title of Director & Chief Scientific Officer.
He is currently the Chairman at Driver Bioengineering, Inc. (since 2019), Director at 3D Bio Holdings, Inc. (since 2020), and Independent Director at Kineta, Inc. (since 2023).
Dr. Dylla's education includes an undergraduate degree from the University of Minnesota and a graduate degree from The University of Alabama at Birmingham.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KINETA, INC.
0.04% | 25-04-2024 | 4 000 ( 0.04% ) | 2 560 $ | 30-04-2024 |
Actieve functies van Scott Dylla
| Bedrijven | Functie | Begin |
|---|---|---|
| KINETA, INC. | Directeur/Bestuurslid | 01-07-2023 |
Driver Bioengineering, Inc.
 Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Driver Bioengineering, Inc. develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor. It engages in building control systems for chimeric antigen receptor (CAR) T-cell therapeutics. The company was founded by Gusti Zeiner, Christina Smolke and Benjamin Wang on May 12, 2015 and is headquartered in Menlo Park, CA. | Voorzitter | 01-06-2019 |
3D Bio Holdings, Inc.
 3D Bio Holdings, Inc. Packaged SoftwareTechnology Services 3D Bio Holdings, Inc. develops term clinical applications. It focuses on whole tissue living implants. The company was founded by Hod Lipson, Larry Bonassar and Daniel L. Cohen and is headquartered in Brooklyn, NY. | Directeur/Bestuurslid | 30-10-2020 |
Eerdere bekende functies van Scott Dylla
| Bedrijven | Functie | Einde |
|---|---|---|
Stemcentrx, Inc.
 Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Oprichter | - |
Opleiding van Scott Dylla
| University of Minnesota | Undergraduate Degree |
| The University of Alabama at Birmingham | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KINETA, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Stemcentrx, Inc.
Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Health Technology |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Driver Bioengineering, Inc. develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor. It engages in building control systems for chimeric antigen receptor (CAR) T-cell therapeutics. The company was founded by Gusti Zeiner, Christina Smolke and Benjamin Wang on May 12, 2015 and is headquartered in Menlo Park, CA. | Health Technology |
3D Bio Holdings, Inc.
3D Bio Holdings, Inc. Packaged SoftwareTechnology Services 3D Bio Holdings, Inc. develops term clinical applications. It focuses on whole tissue living implants. The company was founded by Hod Lipson, Larry Bonassar and Daniel L. Cohen and is headquartered in Brooklyn, NY. | Technology Services |